New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareMOTS-c vs Adamax

MOTS-c vs Adamax

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
MOTS-c
Cognitive Enhancement
Adamax
Summary
MOTS-c is a mitochondria-derived peptide (MDP) encoded within the mitochondrial genome. It acts as a metabolic regulator, improving insulin sensitivity, enhancing exercise capacity, and counteracting age-related metabolic decline. It is often called a 'mitochondrial hormone.'
Adamax is a synthetic neuropeptide related to brain-derived neurotrophic factor (BDNF) signaling pathways. It is explored for cognitive enhancement, neuroprotection, and mood support, with proposed mechanisms involving TrkB receptor activation and enhancement of neuroplasticity similar to endogenous BDNF.
Half-Life
Estimated 1–2 hours
Estimated 1-3 hours (short; peptide degradation)
Admin Route
SubQ
Subcutaneous, Intranasal (research)
Research
Typical Dose
5–15 mg
200-400 mcg per dose
Frequency
3–5 times per week
Once daily or every other day
Key Benefits
  • Improves insulin sensitivity and glucose metabolism
  • Enhances exercise capacity and endurance
  • Reduces age-related metabolic decline
  • Activates AMPK — the master metabolic regulator
  • Promotes fat oxidation
  • Anti-inflammatory effects
  • May extend healthspan via mitochondrial optimization
  • Increases energy and reduces fatigue
  • Proposed enhancement of learning and memory consolidation
  • Neuroprotective via BDNF-TrkB pathway support
  • May improve mood and resilience to stress
  • Potential support for neurogenesis
  • Cognitive clarity and focus enhancement (reported anecdotally)
  • Explored for neurodegeneration and age-related cognitive decline
Side Effects
  • Injection site irritation
  • Fatigue during initial adaptation
  • Unknown long-term profile (limited human data)
  • Limited human safety data; largely anecdotal reports
  • Possible headache or mild overstimulation
  • Sleep disruption with late-day dosing
  • Unknown long-term safety profile
Stacks With